Please select the option that best describes you:
Topics:
Radiation Oncology • Esophageal Cancer • Rectal Cancer • Pancreatic Cancer • Gastrointestinal Malignancies • ASTRO 2024
What are your top takeaways in GI Cancers from ASTRO 2024?
Answer from: Radiation Oncologist at Academic Institution
Neoadjuvant Chemoradiation (CROSS) vs. Perioperative Chemotherapy (FLOT) in Esophageal Adenocarcinoma (EAC): ESOPEC – a Randomised Controlled Prospective Multicentre Phase III Trial published in issue: October 01, 2024 S6
Has now changed the standard of care for adenoCA of the esophagus. CROS...
Sign in or Register to read more
Answer from: Radiation Oncologist at Academic Institution
168 - Neoadjuvant Toripalimab plus Concurrent Chemoradiotherapy in the Locally Advanced Adenocarcinoma of Esophagogastric Junction: A Phase II Trial - This prospective phase II trial evaluated the efficacy and safety of combining neoadjuvant Toripalimab (a PD-1 inhibitor) with chemoradiotherapy fo...
Answer from: Radiation Oncologist at Academic Institution
The landscape for patients with esophageal adenocarcinomas may be shifting towards perioperative chemotherapy and away from neoadjuvant chemoradiation(??)
(LBA 01 – Special Session: Late-breaking Abstracts) LBA09 - Neoadjuvant Chemoradiation (CROSS) vs. Perioperative Chemotherapy (FLOT) in Es...
Answer from: Radiation Oncologist at Academic Institution
ESOPEC: Dr. Brunner presented the results of a randomized controlled prospective multicenter phase III trial that compared the CROSS vs FLOT regiment among patients with esophageal adenocarcinomas. 438 patients with locally advanced disease (cT1N+ or cT2-4a cN0/+) received their designated therapy p...